VACCINE TYPE SHOTS EFFICACY

1 PFIZER BIO N TECH mRNA (Nucleoside modified) x2 90-94%

2 MODERNA mRNA (Nucleoside modified) x2 90-94%
3 JOHNSON & JOHNSON/JANSSEN VIRAL VECTOR(Human Adeno Virus) x1 70-85%
4 ASTRAZENECA / COVISHIELD VIRAL VECTOR(Chimpanzee Adeno Virus) x2 70-90%
5 SPUTNIK-V VIRAL VECTOR(ADENO VIRUS) X2 85-90%
6 SINOVAC/CORONA VAC INACTIVATED VIRUS X2 67-75%
7 NOVAVAX PROTEIN BASED X2 85-89%
8 COVAXIN INACTIVATED VIRUS X2 70-80%
9 ZYDUS CADILA ZyCoV-D - VIRAFIN X3 RUNNING TRIAL

Pfizer BioN Tech

LICENSE-On May 10, 2021, the FDA expanded the emergency use authorization for the Pfizer-BioNTech CO
PRODUCTION-U.S. government has exercised its option for an additional 100 million doses of the Pfizer-Bio
EFFECTS ON PRAGNENT WOMEN- The research team studied a group of 131 women who received the P

MODERNA VACCINE

PRODUCTION- Its increasing its base-case global production estimate from 500 to 600 million doses for 202
LICENSE- The U.S. Food and Drug Administration issued an emergency use authorization allows the Moder
JOHNSON & JOHNSON
LICENSE- The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the thir

PRODUCTION- Johnson &

Johnson’s latest goal is to
produce 94 million doses of its
single-shot vaccine by the end
of May - that is about 7 million
doses ahead of the schedule in
its contract, which calls for
delivery of 87 million doses by
the end of May and the full 100
million by the end of June.

ON PREGNANT WOMEN- Data

are not available to assess the
effects of Janssen COVID-19
vaccine on the pregnant women,
breastfed infant or on milk
production/excretion. We are
awaiting recommendations from
professional societies.
SPUTNIK VACCINE

PRODUCTION - In the first

batch, Dr. Reddy’s has only
received about 1.5 lakh vaccine
doses from its Russian partner
but the company has said that
as per the contract the country
is expected to receive about 250
million doses of the vaccine.

-Pregnant women are still

advised to discuss the risks and
benefits of vaccination with their
clinicians, which includes the
latest evidence on safety and
which vaccines they should
receive.
 COUNTRY COST STORAGE DEVELOPED BY GAP

US - PFIZER GERMANY - BIO Rs 1,431 per dose  −80 and −60 °C (−112stringent regulatory authority (SRA) 
and −76 °F) 12 WEEKS
US Rs 2,715 per dose 2–8 °C (36–46 °F) forUSup to thirty
NIAID and days or −20 °C4 (−4 °F)
BARDA weeks for up to four months,
US, BELGIUM Rs 734 per dose 9°C and 25°C (47°FJanssen Vaccines in
and 77°F) for up to 12
Leiden,
hours. 
Netherlands
UK, SWEDEN Rs 200 per dose   2-8 degrees Celsius Serum Instt.of India 6-12 weeks
RUSSIA Rs. 995 per dose 2-8 degree C The Gamaleya Center 21 DAYS
CHINA Rs 1,027 per dose 2 to 8 degrees CelsiusSinovac Biotech 2 weeks
US Rs 1,114 per dose  2-8 degrees CelsiusNovavax Biotech company, 21 days
INDIA Rs 206 per dose  2-8 degrees CelsiusBharat Biotech 28 days
RUNNING TRIAL Rs 899 per vial  2-8 degrees CelsiusZYDUS BIOTECH PARK,CADILA HEALTHC

tion for the Pfizer-BioNTech COVID-19 Vaccine to include adolescents 12 through 15 years of age also allows the Vaccine to b
0 million doses of the Pfizer-BioNTech COVID-19 Vaccine. This brings the total number of doses to be supplied by the compani
131 women who received the Pfizer or Moderna vaccine, including 84 pregnant, 31 breastfeeding and 16 non-pregnant women.

00 to 600 million doses for 2021. Moderna said it is continuing to invest and add staff to build up to potentially 1 billion doses fo
authorization allows the Moderna COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years of age and olde

authorization (EUA) for the third vaccine for the prevention of COVID-19 caused by (SARS-CoV-2). The EUA allows the Jansse
 PHASETR
INCLUDED AEFI

III 16 and above Common side effects

Booster 18
i and above
ph-III 18 and above Common side effects
6-12 weeks 18 and above Blood clotting
No serious in some
adverse cases
events were registered after
I/II 18 and above vaccination with Sputnik Light.
III 18-59
III 18-84
18 and above Common side effects
III 12-17 AGE

o be supplied by the companies to the U.S. government to 300 million.

and 16 non-pregnant women. All three groups had similar high antibody levels. The study also found no significant differences in

o potentially 1 billion doses for 2021.

uals 18 years of age and older.

). The EUA allows the Janssen COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years of age and older.
ound no significant differences in vaccine side effects between pregnant and non-pregnant women

uals 18 years of age and older.